



UNITED STATES PATENT AND TRADEMARK OFFICE

CL/CL
UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/719,692	11/21/2003	Songzhu An	018781-009530US	1902
7590	10/14/2005		EXAMINER	
BANNER & WITCOFF 1001 G STREET N.W. ELEVENTH FLOOR WASHINGTON, DC 20001			ULM, JOHN D	
			ART UNIT	PAPER NUMBER
			1649	

DATE MAILED: 10/14/2005

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary	Application No.	Applicant(s)	
	10/719,692	AN ET AL.	
	Examiner	Art Unit	
	John D. Ulm	1649	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

1) Responsive to communication(s) filed on 8/16/05.

2a) This action is **FINAL**. 2b) This action is non-final.

3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

4) Claim(s) 1-19 is/are pending in the application.
4a) Of the above claim(s) 1-7 and 12-19 is/are withdrawn from consideration.
5) Claim(s) _____ is/are allowed.
6) Claim(s) 8-11 is/are rejected.
7) Claim(s) _____ is/are objected to.
8) Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

9) The specification is objected to by the Examiner.

10) The drawing(s) filed on _____ is/are: a) accepted or b) objected to by the Examiner.

 Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).

 Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).

11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
a) All b) Some * c) None of:
1. Certified copies of the priority documents have been received.
2. Certified copies of the priority documents have been received in Application No. _____.
3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

1) Notice of References Cited (PTO-892)
2) Notice of Draftsperson's Patent Drawing Review (PTO-948)
3) Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08)
Paper No(s)/Mail Date 6/28/04

4) Interview Summary (PTO-413)
Paper No(s)/Mail Date. ____ .

5) Notice of Informal Patent Application (PTO-152)

6) Other: _____

1) Claims 1 to 19 are pending in the instant application. Claim 11 has been amended as requested by Applicant in the correspondence filed 16 August of 2005.

2) Claims 1 to 7 and 12 to 19 are withdrawn from further consideration pursuant to 37 CFR 1.142(b) as being drawn to a nonelected invention, there being no allowable generic or linking claim. Election was made **without** traverse in the reply filed on 16 August of 2005. Because applicant did not distinctly and specifically point out the supposed errors in the restriction requirement, the election has been treated as an election without traverse (MPEP § 818.03(a)).

3) The title and abstract of the disclosure are objected to because they do not describe the invention now claimed. A revised title and abstract reflecting the specific features of the claimed invention need to be provided. Correction is required. See MPEP § 608.01(b).

The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

4) Claims 8 to 11 are rejected under 35 U.S.C. 112, first paragraph, as failing to comply with the enablement requirement. These claims encompass subject matter that was not described in the specification in such a way as to enable one skilled in the art to which it pertains, or with which it is most nearly connected, to make and/or use the invention. These claims encompass a binding assay that can employ a nucleic acid encoding a "TGR183" protein having other than the entire amino acid sequence presented in SEQ ID NO:6 of the instant application. The text in paragraph 035 of the

instant specification in combination with the claim limitations "at least 70% amino acid sequence identity to SEQ ID NO:6" or "comprises at least 20 contiguous amino acids" thereof allows the limitation "TGR183 polypeptide" to encompass a polypeptide encompass a non-naturally occurring protein whose amino acid sequence deviates from SEQ ID NO:6 by as many as 326 out of 346 amino acid residues. However, the instant specification does not provide the guidance needed to practice the claimed process with a "TGR183" polypeptide comprising anything less than the entire amino acid sequence presented in SEQ ID NO:6. The only manner described in the instant specification of using the claimed method is in the identification of compounds that have potential medicinal use because of their ability to agonize or antagonize the interaction of nicotinic acid with the human "TGR183" protein described therein. The claimed invention is only useful in so far as the "TGR183" protein employed in the claimed assay responds in a manner that is predictive of an authentic physiological response. *In re Fisher*, 427 F.2d 833, 166 USPQ 18 (CCPA 1970), held that

"Inventor should be allowed to dominate future patentable inventions of others where those inventions were based in some way on his teachings, since such improvements while unobvious from his teachings, are still within his contribution, since improvement was made possible by his work; however, he must not be permitted to achieve this dominance by claims which are insufficiently supported and, hence, not in compliance with first paragraph of 35 U.S.C. 112; that paragraph requires that scope of claims must bear a reasonable correlation to scope of enablement provided by specification to persons of ordinary skill in the art; in cases involving predictable factors, such as mechanical or electrical elements, a single embodiment provides broad enablement in the sense that, once imagined, other embodiments can be made without difficulty and their performance characteristics predicted by resort to known scientific law; in cases involving unpredictable factors, such as most chemical reactions and

physiological activity, scope of enablement varies inversely with degree of unpredictability of factors involved."

One of ordinary skill in the art of receptor biology would not reasonably believe that the majority of physical peptide embodiments having at least 70% sequence identity to SEQ ID NO:6, or at least 20 contiguous amino acids thereof are going to be functional, much less be capable of producing an authentic response. Because the instant specification does not identify those amino acid residues in SEQ ID NO:6 which are critical to the structural and functional integrity of a "TGR183" receptor protein comprising that sequence, identify a structurally analogous protein for which this information is known and could be applied to the instant protein by extrapolation, or even provide a single working example of an intentionally modified "TGR183" protein of the instant invention, an artisan can not change even a single residue within the amino acid sequence of SEQ ID NO:6 and predict the effects of that change on the performance of that protein "by resort to known scientific law". Unless one can predict, with reasonable confidence, that an intentionally modified "TGR183" protein is going to produce a response that is predictive of a native human "TGR183" protein, the information obtained from a process that uses that modified protein is of no practical value.

5) Claims 8 to 11 are rejected under 35 U.S.C. 112, first paragraph, as failing to comply with the written description requirement. The claims contain subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor(s), at the time the application was filed, had possession of the claimed invention. The text in paragraph 035 of the instant specification expressly states that the term "TGR183" encompasses proteins and

polynucleotides "from a mammal including, but not limited to, human, mouse, rat, hamster, cow, pig, horse, sheep, or any mammal". The instant specification, however, does not provide an adequate written description of the genus of proteins encompassed by the term "TGR183" as that term is defined in the specification. In the decision of *The Regents of the University of California v. Eli Lilly and Company*, 43 USPQ2d 1398 (CAFC 1997), the court held that:

"To fulfill the written description requirement, a patent specification must describe an invention and do so in sufficient detail that one skilled in the art can clearly conclude that "the inventor invented the claimed invention." *Lockwood v. American Airlines, Inc.*, 107 F.3d 1565, 1572, 41 USPQ2d 1961, 1966 (1997); *In re Gosteli*, 872 F.2d 1008, 1012, 10 USPQ2d 1614, 1618 (Fed. Cir. 1989) ("[T]he description must clearly allow persons of ordinary skill in the art to recognize that [the inventor] invented what is claimed."). Thus, an applicant complies with the written description requirement "by describing the invention, with all its claimed limitations, not that which makes it obvious," and by using "such descriptive means as words, structures, figures, diagrams, formulas, etc., that set forth the claimed invention." *Lockwood*, 107 F.3d at 1572, 41 USPQ2d at 1966.

An adequate written description of a DNA, such as the cDNA of the recombinant plasmids and microorganisms of the '525 patent, "requires a precise definition, such as by structure, formula, chemical name, or physical properties," not a mere wish or plan for obtaining the claimed chemical invention. *Fiers v. Revel*, 984 F.2d 1164, 1171, 25 USPQ2d 1601, 1606 (Fed. Cir. 1993). Accordingly, "an adequate written description of a DNA requires more than a mere statement that it is part of the invention and reference to a potential method for isolating it; what is required is a description of the DNA itself." *Id.* at 1170, 25 USPQ2d at 1606.

Whereas the instant specification and art of record provides a detailed description of a single isolated DNA encoding particular niacin receptor having very specific physical and structural properties, the instant specification does not provide a structural formula which is definitive of the genus of proteins that might be encompassed by the term

"mammalian TGR183". Whereas the instant specification may identify some properties that are common to all members of the G protein-coupled receptor family, it does not identify those defining structural elements that provide the functional and structural properties of a mammalian "TGR183" receptor protein. *In re Clarke*, 148 USPQ 665, (CCPA 1966) held that;

" It appears to be well settled that a single species can rarely, if ever, afford support for a generic claim. *In re Soll*, 25 C.C.P.A. (Patents) 1309, 97 F.2d 623, 38 USPQ 189; *In re Wahlforss et al.*, 28 C.C.P.A. (Patents) 867, 117 F.2d 270, 48 USPQ 397. The decisions do not however fix any definite number of species which will establish completion of a generic invention and it seems evident therefrom that such number will vary, depending on the circumstances of particular cases. Thus, in the case of a small genus such as halogens, consisting of four species, a reduction to practice of three, or perhaps even two, might serve to complete the generic invention, while in the case of a genus comprising hundreds of species, a considerably large number of reductions to practice would probably be necessary."

Considering the very large genus of proteins that could potentially be encompassed by the term "TGR183", the description of a single, naturally occurring species within that genus does not constitute a written description of a representative number of species within that recited genus.

The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

6) Claims 8 to 11 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention. These claims are vague and indefinite in so far as they employ the term "TGR183" as a limitation. Because the instant specification

Art Unit: 1649

does not identify that property or combination of properties which is unique to and, therefore, definitive of a "TGR183" polypeptide an artisan can not determine if a compound which meets all of the other limitations of a claim would then be included or excluded from the claimed subject matter by the presence of this limitation. For example, it is unclear how the limitation "a nicotinic acid receptor comprising the amino acid sequence of SEQ ID NO:6" would differ in scope from the limitation "a TGR183 polypeptide comprising the amino acid sequence of SEQ ID NO:6".

7) The prior art of record, taken individually or in combination, did not suggest or render obvious the subject matter of claims 8 to 11.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to John D. Uilm whose telephone number is (571) 272-0880. The examiner can normally be reached on 9:00AM to 5:30PM.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Janet Andres can be reached on (571) 272-0867. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Application/Control Number: 10/719,692
Art Unit: 1649

Page 8



JOHN ULM
PRIMARY EXAMINER
GROUP 1800